Search Within

Rui Wang

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (7)
  2. Meeting Abstract (6)
  3. Miscellaneous (1)
Groups
  1. Breast Medicine Service (14)
  2. Department of Medicine (14)
  3. Epidemiology and Biostatistics (14)
  4. Solid Tumor Oncology Division (14)
  5. Biostatistics Service (11)
  6. Survivorship Research (11)

More Groups

People
  1. Sujata Patil (8)
  2. Shanu Modi (6)
  3. Clifford Hudis (5)
  4. Komal Jhaveri (4)
  5. Larry Norton (4)
  6. Sarat Chandarlapaty (4)

More People

Years
  1. 2022 (3)
  2. 2021 (1)
  3. 2020 (1)
  4. 2019 (3)
  5. 2018 (2)
  6. 2017 (2)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Annals of Surgical Oncology (3)
  3. Breast Cancer Research (1)
  4. Cancer (1)
  5. Cancer Research (1)
  6. Clinical Breast Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Springer (3)
  3. American Association for Cancer Research (2)
  4. Biomed Central Ltd (1)
  5. Elsevier Inc. (1)
  6. Oxford University Press (1)

More Publishers

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • How often do sentinel lymph node biopsy results affect adjuvant therapy decisions among postmenopausal women with early-stage HR+/HER2− breast cancer in the post-RxPONDER era?
    Journal Article

    Pilewskie, M.; Sevilimedu, V.; Eroglu, I.; Le, T.; Wang, R.; Morrow, M.; Braunstein, L. Z.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • ASO Visual Abstract: How often do sentinel lymph node biopsy results affect adjuvant therapy decisions among postmenopausal women with early-stage HR+/HER2- breast cancer in the post-RxPONDER era?
    Miscellaneous

    Pilewskie, M.; Sevilimedu, V.; Eroglu, I.; Le, T.; Wang, R.; Morrow, M.; Braunstein, L. Z.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • How often do sentinel lymph node biopsy results impact adjuvant therapy decisions among postmenopausal women with early stage, HR+/HER2= breast cancer in the post-RxPonder era?
    Meeting Abstract

    Pilewskie, M.; Sevilimedu, V.; Eroglu, I.; Le, T.; Wang, R.; Morrow, M.; Braunstein, L.
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • A phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Drago, J. Z.; Shah, P. D.; Wang, R.; Pareja, F.; Ratzon, F.; Iasonos, A.; Patil, S.; Rosen, N.; Fornier, M. N.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer
    Journal Article

    Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
    JCO Precision Oncology (2020)

    Fulltext@MSK | Save
  • Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes
    Journal Article

    Lowery, M. A.; Goff, L. W.; Keenan, B. P.; Jordan, E.; Wang, R.; Bocobo, A. G.; Chou, J. F.; O’Reilly, E. M.; Harding, J. J.; Kemeny, N.; more...
    Cancer (2019)

    Fulltext@MSK | Save
  • Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow-up
    Journal Article

    Wang, R.; Smyth, L. M.; Iyengar, N.; Chandarlapaty, S.; Modi, S.; Jochelson, M.; Patil, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Characteristics and prognostic factors for patients with HER2-overexpressing breast cancer and brain metastases in the era of HER2-targeted therapy: An argument for earlier detection
    Journal Article

    Morikawa, A.; Wang, R.; Patil, S.; Diab, A.; Yang, J.; Hudis, C. A.; McArthur, H. L.; Beal, K.; Seidman, A. D.
    Clinical Breast Cancer (2018)

    Fulltext@MSK | Save